Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes ...

Real-world data from the EV-301 trial (NCT03474107), presented at the ASCO 2025 Genitourinary Cancers Symposium, showed that third-line treatment with enfortumab vedotin (Padcev) significantly ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis. Bacillus ...

Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs). This is an ASCO Meeting Abstract from ...

For localized upper tract urothelial carcinoma, there are important considerations for deciding whether a patient ... Eligible patients had non metastatic, high-grade disease on ureteroscopic tumor ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.

Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...